Prevalence and clinical outcomes of white-coat and masked hypertension: Analysis of a large ambulatory blood pressure database

Journal of Clinical Hypertension

Volumn 20, Issue 2, 2018, Pages 297-305

  Tocci, Giuliano ^a,b   Presta, Vivianne ^a   Figliuzzi, Ilaria ^a   Attalla El Halabieh, Nadia ^a   Battistoni, Allegra ^a   Coluccia, Roberta ^b   D'Agostino, Michela ^a   Ferrucci, Andrea ^a   Volpe, Massimo ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

ambulatory blood pressure monitoring; hospitalizations; masked hypertension; myocardial infarction; stroke; sustained hypertension; white coat hypertension

Indexed keywords

ADULT; AGE; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GENDER; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MASKED HYPERTENSION; MIDDLE AGED; PREVALENCE; PRIORITY JOURNAL; SMOKING; WHITE COAT HYPERTENSION; BLOOD PRESSURE; FACTUAL DATABASE; ITALY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RISK FACTOR; URINE;

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; ITALY; MALE; MASKED HYPERTENSION; MIDDLE AGED; MYOCARDIAL INFARCTION; PREVALENCE; RISK FACTORS; STROKE; WHITE COAT HYPERTENSION;

EID: 85042225367     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.13181     Document Type: Article

References (42)

1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
2. Parati G, Stergiou G, O'Brien E, et al. European society of hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014;32:1359-1366.
3. O'Brien E, Parati G, Stergiou G, et al. European society of hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31:1731-1768.
4. Angeli F, Verdecchia P, Gattobigio R, Sardone M, Reboldi G. White-coat hypertension in adults. Blood Press Monit. 2005;10:301-305.
5. Verdecchia P, Schillaci G, Borgioni C, et al. Identification of subjects with white-coat hypertension and persistently normal ambulatory blood pressure. Blood Press Monit. 1996;1:217-222.
6. Mancia G. Reversed white-coat hypertension: definition, mechanisms and prognostic implications. J Hypertens. 2002;20:579-581.
7. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-1357.
8. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-2219.
9. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J. 2008;29:2909-2945.
10. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28:1598-1660.
11. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Eur Heart J. 2007;28:2525-2538.
12. Goldstein LB, Adams R, Alberts MJ, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke. 2006;37:1583-1633.
13. Easton JD, Saver JL, Albers GW, et al. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke. 2009;40:2276-2293.
14. Haider AW, Larson MG, Franklin SS, Levy D. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham heart study. Ann Intern Med. 2003;138:10-16.
15. Wang C, Zhang J, Li Y, et al. Masked hypertension, rather than white-coat hypertension, has a prognostic role in patients with non-dialysis chronic kidney disease. Int J Cardiol. 2017;230:33-39.
16. Cuspidi C, Tadic M, Sala C. Enhanced risk of carotid atherosclerosis associated with white-coat hypertension. J Clin Hypertens. 2016;18:1103-1105.
17. Kushiro T, Kario K, Saito I, et al. Increased cardiovascular risk of treated white coat and masked hypertension in patients with diabetes and chronic kidney disease: the honest study. Hypertens Res. 2017;40:87-95.
18. Muntner P, Booth JN 3rd, Shimbo D, Schwartz JE. Is white-coat hypertension associated with increased cardiovascular and mortality risk? J Hypertens. 2016;34:1655-1658.
19. Ermis N, Afsin A, Cuglan B, et al. Left atrial volume and function in patients with white-coat hypertension assessed by real-time three-dimensional echocardiography. Blood Press Monit. 2016;21:231-237.
20. Briasoulis A, Androulakis E, Palla M, Papageorgiou N, Tousoulis D. White-coat hypertension and cardiovascular events: a meta-analysis. J Hypertens. 2016;34:593-599.
21. Tadic M, Cuspidi C, Ivanovic B, Ilic I, Celic V, Kocijancic V. Influence of white-coat hypertension on left ventricular deformation 2- and 3-dimensional speckle tracking study. Hypertension. 2016;67:592-596.
22. Siven SS, Niiranen TJ, Kantola IM, Jula AM. White-coat and masked hypertension as risk factors for progression to sustained hypertension: the Finn-home study. J Hypertens. 2016;34:54-60.
23. Tang H, Gong WY, Zhang QZ, et al. Prevalence, determinants, and clinical significance of masked hypertension and white-coat hypertension in patients with chronic kidney disease. Nephrology. 2016;21:841-850.
24. Satoh M, Asayama K, Kikuya M, et al. Long-term stroke risk due to partial white-coat or masked hypertension based on home and ambulatory blood pressure measurements: the Ohasama study. Hypertension. 2016;67:48-55.
25. Thomas O, Shipman KE, Day K, Thomas M, Martin U, Dasgupta I. Prevalence and determinants of white coat effect in a large UK hypertension clinic population. J Hum Hypertens. 2016;30:386-391.
26. de la Sierra A, Vinyoles E, Banegas JR, et al. Prevalence and clinical characteristics of white-coat hypertension based on different definition criteria in untreated and treated patients. J Hypertens. 2017;35:2388-2394.
27. Huang Y, Huang W, Mai W, et al. White-coat hypertension is a risk factor for cardiovascular diseases and total mortality. J Hypertens. 2017;35:677-688.
28. Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension. 2006;47:846-853.
29. Mancia G, Bombelli M, Brambilla G, et al. Long-term prognostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements. Hypertension. 2013;62:168-174.
30. Banegas JR, Ruilope LM, de la Sierra A, et al. High prevalence of masked uncontrolled hypertension in people with treated hypertension. Eur Heart J. 2014;35:3304-3312.
31. Tientcheu D, Ayers C, Das SR, et al. Target organ complications and cardiovascular events associated with masked hypertension and white-coat hypertension: analysis from the Dallas heart study. J Am Coll Cardiol. 2015;66:2159-2169.
32. Ohkubo T, Kikuya M, Metoki H, et al. Prognosis of “masked” hypertension and “white-coat” hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. J Am Coll Cardiol. 2005;46:508-515.
33. Krakoff LR. Home blood pressure monitoring: international recognition. Hypertension. 2014;63:670-671.
34. Stergiou GS, Asayama K, Thijs L, et al. Prognosis of white-coat and masked hypertension: international database of home blood pressure in relation to cardiovascular outcome. Hypertension. 2014;63:675-682.
35. Chen Y, Huang YL, Mai WY. Prehypertension or masked hypertension-which is responsible for target-organ damage? Nat Rev Cardiol. 2015;12:497.
36. Viera AJ, Zhu S, Hinderliter AL, Shimbo D, Person SD, Jacobs DR Jr. Diurnal blood pressure pattern and development of prehypertension or hypertension in young adults: the Cardia study. J Am Soc Hypertens. 2011;5:48-55.
37. Saeed S, Waje-Andreassen U, Fromm A, Oygarden H, Naess H, Gerdts E. Prevalence and covariates of masked hypertension in ischemic stroke survivors: the Norwegian stroke in the young study. Blood Press Monit. 2016;21:244-250.
38. Mancia G, Bombelli M, Facchetti R, et al. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension. 2009;54:226-232.
39. -2011 hypertension surveys. J Hum Hypertens. 2015;29:696-701.
40. Tocci G, Muiesan ML, Parati G, et al. Trends in prevalence, awareness, treatment, and control of blood pressure recorded from 2004 to 2014 during world hypertension day in Italy. J Clin Hypertens (Greenwich). 2016;18:551-556.
41. Basile JN, Bloch MJ. NHANES data highlight the clinical characteristics of those with poorly controlled hypertension. J Clin Hypertens (Greenwich). 2012;14:267-268.
42. Whyte JL, Lapuerta P, L'Italien GJ, Franklin SS. The challenge of controlling systolic blood pressure: data from the national health and nutrition examination survey (NHANES III), 1988–1994. J Clin Hypertens (Greenwich). 2001;3:211-216.